ENSG
VENTE TOTALE: 867 titres (~152 072,52 $ US)
- Insiders
- Blouin Ann Scott, Agwunobi John O, Parkinson Mark Vincent
- Total bought
- —
- Total sold
- $152,073
- Last activity
- 2026-07-27
- Last synced
-
2026-08-02 18:09:48
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-02
ENSG shows solid operational momentum with a Q2 earnings beat and a raised 2026 outlook driven by occupancy gains and acquisitions, but the catalyst confidence is moderated (0.7) by ongoing law firm securities…
The first sentence of the analysis written for ENSG on 2026-08-02 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 15.8% | 15.7% | 15.8% | 17.1% | 17.8% | |
| Ebit Margin | 9.2% | 9.3% | 7.5% | 9.9% | 10.1% | |
| Ebitda Margin | 11.2% | 11.2% | 9.5% | 11.9% | 12.2% | |
| Operating Profit Margin | 8.4% | 8.4% | 6.8% | 9.8% | 9.9% | |
| Pretax Profit Margin | 9.0% | 9.1% | 7.3% | 9.6% | 9.8% | |
| Continuous Operations Profit Margin | 6.8% | 7.0% | 5.6% | 7.4% | 7.5% | |
| Net Profit Margin | 6.8% | 7.0% | 5.6% | 7.4% | 7.4% | |
| Bottom Line Profit Margin | 6.8% | 7.0% | 5.6% | 7.4% | 7.4% | |
| Current Ratio | 1.423 | 1.557 | 1.425 | 1.342 | 1.223 | |
| Quick Ratio | 1.423 | 1.557 | 1.425 | 1.342 | 1.223 | |
| Solvency Ratio | 0.139 | 0.135 | 0.105 | 0.130 | 0.137 | |
| Cash Ratio | 0.563 | 0.625 | 0.694 | 0.543 | 0.501 | |
| Price To Earnings Ratio | 29.033 | 25.259 | 29.843 | 23.132 | 23.518 | |
| Price To Earnings Growth Ratio | 2.064 | 0.633 | -3.699 | 1.588 | 1.974 | |
| Forward Price To Earnings Growth Ratio | 2.064 | 0.633 | -3.699 | 1.588 | 1.974 | |
| Price To Earnings Diluted Ratio | 29.829 | 25.949 | 30.742 | 23.952 | 24.550 | |
| Price To Earnings Diluted Growth Ratio | 2.121 | 0.644 | -4.048 | 1.546 | 2.087 | |
| Price To Book Ratio | 4.473 | 4.097 | 4.190 | 4.163 | 4.482 | |
| Price To Sales Ratio | 1.974 | 1.767 | 1.676 | 1.716 | 1.741 | |
| Price To Free Cash Flow Ratio | 26.928 | 39.838 | 23.110 | 28.074 | 22.193 | |
| Price To Operating Cash Flow Ratio | 17.691 | 21.681 | 16.596 | 19.055 | 16.594 | |
| Debt To Assets Ratio | 0.761 | 0.423 | 0.448 | 0.456 | 0.444 | |
| Debt To Equity Ratio | 1.862 | 1.075 | 1.254 | 1.262 | 1.240 | |
| Debt To Capital Ratio | 0.651 | 0.518 | 0.556 | 0.558 | 0.553 | |
| Long Term Debt To Capital Ratio | 0.483 | 0.072 | 0.089 | 0.107 | 0.130 | |
| Financial Leverage Ratio | 2.448 | 2.542 | 2.800 | 2.768 | 2.793 | |
| Working Capital Turnover Ratio | 12.770 | 11.731 | 14.590 | 19.167 | 38.302 | |
| Operating Cash Flow Ratio | 0.631 | 0.467 | 0.513 | 0.468 | 0.527 | |
| Operating Cash Flow Sales Ratio | 0.112 | 0.081 | 0.101 | 0.090 | 0.105 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.657 | 0.544 | 0.718 | 0.679 | 0.748 | |
| Debt Service Coverage Ratio | 37.379 | 31.594 | 24.119 | 23.095 | 24.560 | |
| Interest Coverage Ratio | 53.243 | 43.242 | 31.577 | 33.235 | 38.030 | |
| Short Term Operating Cash Flow Coverage Ratio | 133.492 | 84.970 | 95.358 | 70.181 | 73.320 | |
| Operating Cash Flow Coverage Ratio | 0.136 | 0.176 | 0.201 | 0.173 | 0.218 | |
| Capital Expenditure Coverage Ratio | 2.915 | 2.194 | 3.547 | 3.113 | 3.964 | |
| Dividend Paid And Capex Coverage Ratio | 2.713 | 2.020 | 3.163 | 2.733 | 3.399 | |
| Dividend Payout Ratio | 0.042 | 0.046 | 0.062 | 0.054 | 0.059 | |
| Enterprise Value Multiple | 24.006 | 18.886 | 21.551 | 17.900 | 17.385 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 15.8% | ▲0.1% | ▼-0.7% |
| Ebit Margin | 9.2% | ▼-0.1% | ▼-0.0% |
| Ebitda Margin | 11.2% | -0.0% | ▲0.0% |
| Operating Profit Margin | 8.4% | -0.0% | ▼-0.3% |
| Pretax Profit Margin | 9.0% | ▼-0.1% | ▲0.1% |
| Continuous Operations Profit Margin | 6.8% | ▼-0.2% | ▼-0.1% |
| Net Profit Margin | 6.8% | ▼-0.2% | ▼-0.1% |
| Bottom Line Profit Margin | 6.8% | ▼-0.2% | ▼-0.1% |
| Current Ratio | 1.423 | ▼-0.135 | ▲0.029 |
| Quick Ratio | 1.423 | ▼-0.135 | ▲0.029 |
| Solvency Ratio | 0.139 | ▲0.004 | ▲0.010 |
| Cash Ratio | 0.563 | ▼-0.061 | ▼-0.022 |
| Price To Earnings Ratio | 29.033 | ▲3.775 | ▲2.876 |
| Price To Earnings Growth Ratio | 2.064 | ▲1.431 | ▲1.552 |
| Forward Price To Earnings Growth Ratio | 2.064 | ▲1.431 | ▲1.552 |
| Price To Earnings Diluted Ratio | 29.829 | ▲3.880 | ▲2.824 |
| Price To Earnings Diluted Growth Ratio | 2.121 | ▲1.477 | ▲1.651 |
| Price To Book Ratio | 4.473 | ▲0.376 | ▲0.192 |
| Price To Sales Ratio | 1.974 | ▲0.207 | ▲0.199 |
| Price To Free Cash Flow Ratio | 26.928 | ▼-12.909 | ▼-1.100 |
| Price To Operating Cash Flow Ratio | 17.691 | ▼-3.989 | ▼-0.632 |
| Debt To Assets Ratio | 0.761 | ▲0.338 | ▲0.254 |
| Debt To Equity Ratio | 1.862 | ▲0.787 | ▲0.523 |
| Debt To Capital Ratio | 0.651 | ▲0.133 | ▲0.083 |
| Long Term Debt To Capital Ratio | 0.483 | ▲0.412 | ▲0.307 |
| Financial Leverage Ratio | 2.448 | ▼-0.094 | ▼-0.222 |
| Working Capital Turnover Ratio | 12.770 | ▲1.039 | ▼-6.542 |
| Operating Cash Flow Ratio | 0.631 | ▲0.164 | ▲0.110 |
| Operating Cash Flow Sales Ratio | 0.112 | ▲0.030 | ▲0.014 |
| Free Cash Flow Operating Cash Flow Ratio | 0.657 | ▲0.113 | ▼-0.012 |
| Debt Service Coverage Ratio | 37.379 | ▲5.785 | ▲9.229 |
| Interest Coverage Ratio | 53.243 | ▲10.001 | ▲13.378 |
| Short Term Operating Cash Flow Coverage Ratio | 133.492 | ▲48.522 | ▲42.028 |
| Operating Cash Flow Coverage Ratio | 0.136 | ▼-0.040 | ▼-0.045 |
| Capital Expenditure Coverage Ratio | 2.915 | ▲0.721 | ▼-0.231 |
| Dividend Paid And Capex Coverage Ratio | 2.713 | ▲0.694 | ▼-0.092 |
| Dividend Payout Ratio | 0.042 | ▼-0.004 | ▼-0.011 |
| Enterprise Value Multiple | 24.006 | ▲5.120 | ▲4.060 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $9.98B | $7.53B | $6.25B | $5.19B | $4.57B | |
| Enterprise value | $13.63B | $9.04B | $7.61B | $6.45B | $5.58B | |
| EV / Sales | 2.70x | 2.12x | 2.04x | 2.13x | 2.12x | |
| EV / Op. cash flow | 24.16x | 26.03x | 20.21x | 23.67x | 20.23x | |
| EV / Free cash flow | 36.78x | 47.83x | 28.14x | 34.87x | 27.06x | |
| EV / EBITDA | 24.01x | 18.89x | 21.55x | 17.90x | 17.39x | |
| Net debt / EBITDA | 6.43x | 3.15x | 3.85x | 3.49x | 3.13x | |
| Current ratio | 1.42x | 1.56x | 1.43x | 1.34x | 1.22x | |
| Income quality | 1.64x | 1.16x | 1.79x | 1.21x | 1.39x | |
| Graham number | $73 | $62 | $48 | $46 | $39 | |
| Graham net-net | -$38 | -$33 | -$32 | -$29 | -$24 | |
| Tax burden | 75.5% | 77.2% | 76.8% | 77.7% | 75.4% | |
| Interest burden | 98.3% | 97.9% | 97.1% | 97.0% | 97.4% | |
| Working capital | $378.0M | $414.2M | $312.2M | $199.1M | $116.6M | |
| Invested capital | $4.28B | $3.67B | $3.24B | $2.73B | $2.21B | |
| Return on assets | 6.3% | 6.4% | 5.0% | 6.5% | 6.8% | |
| Operating ROA | 8.4% | 8.1% | 6.7% | 9.4% | 9.7% | |
| Return on tangible assets | 6.4% | 6.5% | 5.1% | 6.7% | 7.0% | |
| Return on equity | 15.4% | 16.2% | 14.0% | 18.0% | 19.1% | |
| Return on invested capital | 6.9% | 6.9% | 5.6% | 7.8% | 8.4% | |
| Return on capital employed | 9.3% | 9.1% | 7.4% | 10.3% | 11.2% | |
| Earnings yield | 3.4% | 4.0% | 3.3% | 4.3% | 4.3% | |
| Free cash flow yield | 3.7% | 2.5% | 4.3% | 3.6% | 4.5% | |
| Capex / Op. cash flow | 34.3% | 45.6% | 28.2% | 32.1% | 25.2% | |
| Capex / Depreciation | 185.5% | 188.1% | 146.7% | 140.4% | 124.2% | |
| Capex / Sales | 3.8% | 3.7% | 2.8% | 2.9% | 2.6% | |
| SG&A / Sales | 5.3% | 5.3% | 7.1% | 5.2% | 5.8% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.0% | 0.9% | 0.8% | 0.8% | 0.7% | |
| Intangibles / Total assets | 1.9% | 2.3% | 2.0% | 2.4% | 2.3% | |
| Days sales outstanding | 46d | 49d | 47d | 49d | 46d | |
| Days payables outstanding | 8d | 10d | 11d | 11d | 10d | |
| Operating cycle | 46d | 49d | 47d | 49d | 46d | |
| Cash conversion cycle | 38d | 39d | 37d | 38d | 36d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+32.6%EV / Sales ▲+27.1%EV / EBITDA ▲+27.1%EV / Op. cash flow ▼-1.868Earnings yield ▼-0.005Graham number ▲+10.577
Profitability
Return on equity ▼-0.008Return on assets ▼-0.001Return on invested capital -0.000Return on capital employed ▲+0.002Operating ROA ▲+0.003Income quality ▲+0.476Tax burden ▼-0.017
Efficiency
Days sales outstanding ▼-2.856Days payables outstanding ▼-1.710Operating cycle ▼-2.856Cash conversion cycle ▼-1.146Capex / Sales ▲+0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.135Net debt / EBITDA ▲+3.273Working capital ▼-36246000.000Invested capital ▲+605143000.000Intangibles / Total assets ▼-0.003
Change over 5 years
Valuation
Market cap ▲+118.2%EV / Sales ▲+27.0%EV / EBITDA ▲+38.1%EV / Op. cash flow ▲+3.929Earnings yield ▼-0.008Graham number ▲+33.716
Profitability
Return on equity ▼-0.037Return on assets ▼-0.005Return on invested capital ▼-0.015Return on capital employed ▼-0.019Operating ROA ▼-0.013Income quality ▲+0.245Tax burden +0.000
Efficiency
Days sales outstanding ▲+0.302Days payables outstanding ▼-1.482Operating cycle ▲+0.302Cash conversion cycle ▲+1.783Capex / Sales ▲+0.012R&D / Sales n/a
Balance-sheet strength
Current ratio ▲+0.200Net debt / EBITDA ▲+3.302Working capital ▲+261317000.000Invested capital ▲+2066250000.000Intangibles / Total assets ▼-0.004
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-07-31 Here's Why Ensign Group (ENSG) is a Strong Value Stock Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-07-31 Kaplan Fox Notifies The Ensign Group, Inc. (ENSG) Investors of a Securities Investigation into the Company New York, New York--(Newsfile Corp. - July 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Ensign investor and have suffered losses, or if you have information that could assist in the Ensign investigation, you may CLICK HERE to contact us.
- 2026-07-30 Ensign Investor News: If You Have Suffered Losses in The Ensign Group, Inc. (NASDAQ: ENSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-07-30 ENSG Q2 Earnings Beat Estimates on Growing Occupancy, '26 View Raised Ensign Group beats Q2 earnings and raises its 2026 outlook as higher occupancy, patient days and acquired facilities drive revenue growth.
- 2026-07-29 The Ensign Group, Inc. (ENSG) Q2 2026 Earnings Call Transcript The Ensign Group, Inc. (ENSG) Q2 2026 Earnings Call Transcript
- 2026-07-29 The Ensign Group Q2 Earnings Call Highlights The Ensign Group NASDAQ: ENSG raised its 2026 earnings and revenue outlook after reporting second-quarter gains in revenue, earnings and occupancy, while highlighting continued acquisition activity and clinical quality measures across its skilled nursing portfolio.
- 2026-07-29 Kaplan Fox is Investigating The Ensign Group, Inc. (ENSG) and Encourages Investors Who Suffered Losses to Contact the Firm New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Ensign investor and have suffered losses, or if you have information that could assist in the Ensign investigation, you may CLICK HERE to contact us.
- 2026-07-29 ENSG INVESTIGATION: Ensign Securities Fraud Investigation into Regulatory Issues is Ongoing – Contact BFA Law if You Lost Money NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops. If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.
- 2026-07-28 Rosen Law Firm Encourages The Ensign Group, Inc. Investors to Inquire About Securities Class Action Investigation - ENSG NEW YORK, July 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public. So What: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 2026-07-27 Ensign 投資者消息：若您因 The Ensign Group, Inc. (NASDAQ: ENSG) 蒙受損失，請聯絡 Rosen Law Firm 了解您的權益 紐約, July 28, 2026 (GLOBE NEWSWIRE) -- 事因：全球投資者權益律師事務所 Rosen Law Firm 繼續代表 The Ensign Group, Inc. (NASDAQ: ENSG) 的股東，調查 Ensign 可能向投資公眾發佈重大誤導性業務資訊並就此引發的潛在證券索賠。 影響：如果您購買了 Ensign 證券，您可能有權獲得賠償，並透過勝訴收費安排，免去任何自付費用或開支。Rosen Law Firm 正準備提出集體訴訟，期望為投資者討回損失。 下一步行動：如欲加入潛在集體訴訟，請造訪 https://rosenlegal. com/cases/the-ensign-group-inc/join 或免費致電 866-767-3653 或電郵至 case@rosenlegal. com 與 Phillip Kim 律師聯絡，了解關於此集體訴訟的資訊。 事件概覽：2026 年 6 月 8 日，Investing. com 發佈了一則題為「Ensign Group 股價遭沽空報告拖累急挫」的報道。文章提到，Ensign 股價下跌是由於「沽空機構 Hunterbrook 發表報告，指稱該養老院營運商的經營模式實質上是依靠削減病人護理質素及玩弄質素評分。」 此外，文章提到，Hunterbrook「發佈了一項為期五個月的調查結果，指公司盈利來自院舍人手短缺，並把納稅人的金錢撥給高層及相關人士。報告指控有病人因此受苦，甚至喪生。」 在上述消息傳出後，Ensign Group 股價在 2026 年 6 月 8 日下跌 8.